Abstract
Macrophages have an important role in the pathogenesis of hypertension and associated end-organ damage via the activation of the Toll-like receptors, such as Toll-like receptor-4 (TLR4). Accumulating evidence suggests that the angiotensin AT2 receptor (AT2R) has a protective role in pathological conditions involving inflammation and tissue injury. We have recently shown that AT2R stimulation is renoprotective, which occurs in part via increased levels of anti-inflammatory interleukin-10 (IL-10) production in renal epithelial cells; however, the role of AT2R in the inflammatory activity of macrophages is not known. The present study was designed to investigate whether AT2R activation stimulates an anti-inflammatory response in TLR4-induced inflammation. The effects of the anti-inflammatory mechanisms that occurred following pre-treatment with the AT2R agonist Compound 21 (C21) (1 μmol ml−1) on the cytokine profiles of THP-1 macrophages after activation by lipopolysaccharide (LPS) (1 μg ml−1) were studied. The AT2R agonist dose-dependently attenuated LPS-induced tumor necrosis factor-α (TNF-α) and IL-6 production but increased IL-10 production. IL-10 was critical for the anti-inflammatory effects of AT2R stimulation because the IL-10-neutralizing antibody dose-dependently abolished the AT2R-mediated decrease in TNF-α levels. Further, enhanced IL-10 levels were associated with a sustained, selective increase in the phosphorylation of extracellular signal-regulated kinase (ERK1/2) but not p38 mitogen-activated protein kinase (MAPK). Blocking the activation of ERK1/2 before C21 pre-treatment completely abrogated this increased IL-10 production in response to the AT2R agonist C21, while there was a partial reduction in IL-10 levels following the inhibition of p38. We conclude that AT2R stimulation exerts a novel anti-inflammatory response in THP-1 macrophages via enhanced IL-10 production as a result of sustained, selective ERK1/2 phosphorylation, which may have protective roles in hypertension and associated tissue injury.
Similar content being viewed by others
Introduction
Chronic inflammation, which is characterized by elevated cytokine and chemokine expression, has been shown to have a central role in the pathophysiology of hypertension and associated end-organ damage, including renal injury.1, 2, 3, 4 At the cellular level, chronic inflammation is mediated largely by macrophages. Additionally, macrophage infiltration invariably accompanies hypertensive organ damage, such as that which occurs to blood vessels,5 the heart6 and the kidneys.7 Moreover, circulating monocytes are activated in hypertensive patients and produce increased amounts of pro-inflammatory cytokines, including tumor necrosis factor-α (TNF-α), interleukin-1 (IL-1) and transforming growth factor-β.8 Recent evidence indicates that rather than being a mere consequence of elevated blood pressure, macrophage activation is actually a causative factor in the development of hypertension.9,10
The renin-angiotensin system is a critical hormonal system that regulates blood pressure, and it is abnormally activated in hypertensive patients. Macrophages also express all major components of the renin-angiotensin system.11 Angiotensin II (Ang II) has been demonstrated to participate in the activation and pro-inflammatory polarization of leukocytes via the AT1 receptor (AT1R).12, 13, 14 However, the precise cellular mechanisms underlying these activities are not well defined. One potential inflammatory pathway that has been implicated in hypertension is the activation of innate immune receptors, specifically Toll-like receptor-4 (TLR4) signaling,15 which leads to the production of an array of pro-inflammatory mediators. In fact, peripheral monocyte TLR4 expression is markedly increased in hypertensive patients compared with normotensive controls.16 Furthermore, Ang II has been shown to upregulate TLR4 expression via the AT1R17 and exacerbate pro-inflammatory cytokine production in response to TLR4 activation by lipopolysaccharide (LPS) in macrophages.18 Accumulating evidence suggests that the AT2 receptor (AT2R), which is generally considered to be a functional antagonist of the AT1R, exerts an anti-inflammatory response.19, 20, 21 We have previously shown that the stimulation of the AT2R by the selective agonist Compound 21 (C21) attenuates pro-inflammatory signaling in response to the LPS activation of proximal tubule epithelial cells via increased IL-10 production.22 However, the abilities of the AT2R to induce IL-10 production and exert an anti-inflammatory response in LPS-activated macrophages have not been investigated to date.
In macrophages, multiple pathways exist to promote IL-10 production.23 The activation of mitogen-activated protein kinases (MAPKs), specifically via p38 and extracellular signal-regulated kinase (ERK1/2), has been shown to be required to increase IL-10 levels in macrophages, and the inhibition of either of these MAPKs impairs IL-10 production.24, 25, 26, 27, 28 Moreover, increased ERK1/2 activation correlates well with the extent of IL-10 production in this cell type.23 Because the AT2R has been linked to a sustained increase in ERK1/2 phosphorylation, this may be a potential molecular mechanism by which the AT2R agonist can enhance IL-10 production in macrophages.
The present study was designed to test the hypothesis that the stimulation of the AT2R attenuates TLR4-mediated pro-inflammatory cytokine production in macrophages via increased IL-10 production. We evaluated the effects of C21 on the production of TNF-α, IL-6 and IL-10 in LPS-activated THP-1 macrophages. We demonstrated that pre-treatment with C21 significantly attenuated the levels of pro-inflammatory cytokines. This was found to be dependent upon increased IL-10 production in response to AT2R activation. Moreover, this upregulation of IL-10 was mediated by a sustained, selective increase in ERK1/2 phosphorylation.
Materials and methods
Cell culture and treatments
The human THP-1 monocytic cell line (ATCC) was cultured in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum and an antibiotic/antimycotic cocktail (100 U ml−1 penicillin, 100 μg ml−1 streptomycin and 250 ng ml−1 amphotericin B) at 37 °C in a humidified atmosphere with 5% CO2. Cell culture media and supplements were all purchased from HyClone (ThermoFisher Scientific, Waltham, MA, USA). To differentiate monocytes from macrophages, 5 × 105 cells per well were treated with 40 nmol l−1 PMA (phorbol-12-myristate-13-acetate) (Sigma, St Louis, MO, USA) for 48 h in RPMI-1640 containing 5% fetal bovine serum. At the end of the 48-h incubation period, the medium was aspirated, and the cells were washed with RPMI-1640 without fetal bovine serum or antibiotics/antimycotics and were then incubated in this medium for 6–8 h. To eliminate pre-existing cytokine production, the medium was replaced by fresh serum-free medium before the treatments were initiated. LPS (1 μg ml−1) (E. coli O55:B5; Sigma) was used to induce the production of pro-inflammatory cytokines. The cells were pre-treated with C21 (custom synthesized) for 60 min before the addition of LPS, and the drug remained in the medium for the entire duration of the treatment. Treatments with specific inhibitors, including 1 μmol l−1 candesartan (an AT1R antagonist; AstraZeneca, Wilmington, DE, USA), 10 μmol l−1 PD123319 (an AT1R antagonist; Pfizer, New York, NY, USA), 10 μmol l−1 SB203580 (a p38 inhibitor; Cell Signaling Technology, Danvers, MA, USA) and 10 μmol l−1 PD98059 (an MEK (MAPK/ERK kinase) inhibitor; Cell Signaling Technology) were carried out as indicated in the text and figure legends.
Immunoblotting
Macrophages were washed twice with PBS and lysed on a plate using ice-cold cell lysis buffer (Cell Signaling Technology) containing protease (Roche, Indianapolis, IN, USA)- and phosphatase (Sigma)-inhibitor cocktails. Equal amounts of protein in Laemmli buffer were loaded per well (15 μg per lane for AT1R, 45 μg per lane for AT2R and 30 μg per lane for ERK1/2 and p38 MAPK) and separated by SDS-PAGE using a Tris-glycine system. Proteins were then transferred onto a PVDF membrane using the wet transfer protocol. The membrane was incubated in 5% non-fat dry milk in PBST for 1 h, followed by incubation overnight with primary antibodies against AT1R (Biomolecular Integrations, Little Rock, AR, USA), AT2R (EZ Biolabs, Carmel, IN, USA), p-ERK1/2 (Cell Signaling Technology), p-p38 MAPK (Cell Signaling Technology) at 1:1000 dilutions. An antibody against inducible nitric oxide synthase (iNOS) (Cell Signaling Technology) was used at 1:500, while that against macrophage mannose receptor (MMR; Abcam, Cambridge, MA, USA) was used at a 1:200 dilution. This was followed by a wash with PBST and a 1-h incubation with appropriate HRP-conjugated secondary antibodies (Santa Cruz Biotechnology). Chemiluminescence was detected by the addition of Luminol HRP substrate (Santa Cruz Biotechnology) and quantified by a software-assisted densitometric analysis (Alpha Innotech, San Leandro, CA, USA). To ensure equal loading, the blots were stripped and re-probed for β-actin (BioVision, Milpitas, CA, USA) for AT1R and AT2R and total-p38 and total-ERK1/2 for p-p38 and p-ERK1/2, respectively (Cell Signaling Technology).
Enzyme-linked immunosorbent assay
The cytokines in the medium were assessed by a kit-based enzyme-linked immunosorbent assay (ELISA) according to the manufacturer’s protocols (R&D Systems, Minneapolis, MN, USA).
mRNA expression by RT–PCR
Total RNA from the cells was extracted using the RNeasy kit (Qiagen, Valencia, CA, USA) according to the manufacturer’s protocol. cDNA was synthesized by RT–PCR from 1 μg of total RNA using the SuperScript III First-Strand Synthesis System (Life Technologies, Grand Island, NY, USA). This cDNA was used as a template for the quantitative RT–PCR analysis of the gene expressions of TNFA, IL6 and IL10 using TaqMan gene expression assays (Applied Biosystems, Grand Island, NY, USA). Relative quantifications were determined using the delta-delta Ct method with GAPDH as a control.
Statistical analysis
The data are presented as the mean±s.e.m. Student’s t-test was used to compare the mean values of two groups. One-way ANOVA with a post hoc test (Tukey’s) for multiple comparisons was used to compare variations between more than two groups. A value of P<0.05 was considered to be statistically significant with n=5–8 experiments per group.
Results
Expression of angiotensin AT1R and AT2R in THP-1 macrophages
THP-1 macrophages express both AT1R and AT2R. The expressions of both receptor subtypes were not altered by the C21 or LPS treatments (Figures 1a and b); however, the C21 pre-treatment lowered AT1R expression by ~50% in response to LPS (Figure 1a), which is in agreement with a number of previous reports demonstrating the AT2R-mediated downregulation of AT1R in pathophysiological conditions.29, 30, 31
Effects of AT2R agonist (C21) and AT1R antagonist (candesartan) on cytokine production by LPS-activated THP-1 macrophages
THP-1 macrophages were treated with LPS (1 μg ml−1) for 24 h to induce the expression of pro-inflammatory cytokines (TNF-α and IL-6) and the anti-inflammatory cytokine IL-10. Pre-treatment with the AT2R agonist C21 (1 μmol l−1) attenuated the LPS-induced TNF-α and IL-6 production by ~33 and 50%, respectively, with a concurrent 75% increase in IL-10 production. This anti-inflammatory response was blocked by the AT2R antagonist PD123319 (10 μmol l−1), suggesting the presence of an AT2R-mediated effect. However, pre-treatment with the AT1R antagonist candesartan (1 μmol l−1) did not alter the cytokine levels in response to LPS (Figures 2a–c). In an additional set of experiments, C21 (1 μmol l−1) was administered 1 h after LPS administration to determine the effects of AT2R stimulation following the initiation of inflammatory pathways. IL-6, but not TNF-α, was significantly attenuated when the macrophages were treated with C21 post-LPS administration. IL-10 levels appeared to be only modestly increased (Supplementary Figure S1).
The anti-inflammatory effects of an AT2R agonist (C21) on cytokine production by LPS-activated THP-1 macrophages are mediated by increased IL-10 production
Pre-treatment with the AT2R agonist C21 dose-dependently (0.1–10 μmol l−1) attenuated the production of TNF-α (Figure 3a), while IL-10 production was concurrently enhanced (Figure 3b) in the LPS-activated THP-1 macrophages at 24 h post LPS administration. Pre-treatment with C21 before LPS activation resulted in lower TNF-α levels, which were observed as early as 60 min post LPS administration, and this trend continued for up to 4 h (Figure 3c). The cells pre-treated with C21 for 1 h produced measurable amounts of anti-inflammatory IL-10 at the time of LPS addition, and the IL-10 levels continued to be elevated for up to 4 h compared with the LPS-treated control cells (Figure 3d). Thus, this AT2R agonist exerts anti-inflammatory effects on early cytokine production in THP-1 macrophages, and this response is dose dependent.
Cytokine production at the levels of mRNA and the protein released into the media was assessed at 24 h post LPS activation to determine the effects of the chronic stimulation of AT2R. C21 pre-treatment significantly attenuated pro-inflammatory TNF-α and IL-6 mRNA levels in addition to their protein expression levels (Figures 4a, b, d and e). Conversely, the IL-10 level in the media was significantly higher for the C21 pre-treated cells following LPS stimulation (Figure 4f). Interestingly, IL-10 mRNA expression was higher in the C21-treated cells, even in the absence of LPS activation (Figure 4c), although this did not translate into higher IL-10 protein expression in this treatment group (Figure 4f). Furthermore, a neutralizing antibody to IL-10 dose-dependently ameliorated the effects of C21 on LPS-induced TNF-α production (Figure 5). Thus, the increase in IL-10 production in response to C21 in the presence of LPS appears to be critical for attenuating the anti-inflammatory response to LPS.
Involvement of p38 and ERK1/2 MAPKs in the AT2R-mediated increase in IL-10 production
The activation of MAPKs, specifically p38 and ERK1/2, has been shown to be a key requirement for the regulation of IL-10 production in macrophages.25,28,32,33 LPS treatment led to the rapid phosphorylation of p38 and ERK1/2; these activities peaked at 30 min post LPS treatment and returned to basal levels by 2 h post LPS treatment (Figures 6a, b, 7a and b). C21 pre-treatment delayed the peak of p38 phosphorylation to 1 h post LPS treatment (Figures 6a and b). Incubation with a p38 inhibitor (SB203580; 10 μmol l−1) before C21 pre-treatment partially abolished the C21-mediated increase in IL-10 at 24 h post LPS activation (Figure 6c).
However, C21 pre-treatment resulted in a delayed, sustained increase in ERK1/2 phosphorylation (Figures 7a and b), which persisted for up to 24 h following LPS treatment (Figure 7c). Moreover, pre-incubation of the cells with an MEK inhibitor (PD98059; 10 μmol l−1), which prevented ERK1/2 activation, before C21 pre-treatment completely abolished the C21-mediated increase in IL-10 at 24 h post LPS activation (Figure 7d), suggesting that the sustained, selective ERK1/2 phosphorylation associated with the AT2R agonist is essential for the increase in IL-10 production. C21 treatment alone did not induce ERK1/2 phosphorylation at 24 h (Figure 7c) or at any earlier time points (data not shown), suggesting that LPS-mediated signaling is required for C21 to exert its anti-inflammatory effects.
Effects of AT2R (C21) agonist pre-treatment on macrophage polarization
Depending on the stimulating factors, macrophages can be polarized to produce predominantly pro-inflammatory or anti-inflammatory mediators. These phenotypes are broadly classified as ‘classically’ activated M1 and ‘alternatively’ activated M2 macrophages, respectively. M1 macrophages express high levels of iNOS, while expression of the macrophage mannose receptor (MMR) is upregulated in M2 macrophages. Consequently, these proteins may be used as phenotypic markers. LPS (1 μg ml−1) treatment resulted in an approximate fivefold increase in iNOS expression, which was prevented when the cells were pre-incubated with C21 (1 μg ml−1) for 1 h (Figure 8a). The expression of MMR was markedly lower in LPS-treated cells but was ~50% higher in C21-treated macrophages, which was independent of LPS stimulation (Figure 8b).
Discussion
Macrophages have an important role in the initiation and progression of hypertension and associated end-organ damage via the activation of TLR4-mediated pro-inflammatory signaling. Macrophages express AT2Rs,11 which have been demonstrated to attenuate TLR-mediated pro-inflammatory cytokine production in proximal tubule epithelial cells.22 In the present study, we have demonstrated that the pre-treatment of THP-1 macrophages with the AT2R agonist C21 attenuates TNF-α and IL-6 production in response to the activation of TLR4 by LPS. These effects are mainly a result of the increased IL-10 production by macrophages via a sustained, selective increase in ERK1/2 phosphorylation.
Ang II has been documented to promote pro-inflammatory cytokine and chemokine production via the AT1R in a manner similar to TLR4-mediated signaling in a number of tissues, including endothelial cells,34,35 renal tubular epithelial cells,36 dendritic cells37, 38, 39 and T lymphocytes.40, 41, 42 However, its precise role in association with macrophages/monocytes is controversial. The incubation of monocytes with Ang II has been shown to induce the expression of the chemokine monocyte chemoattractant protein-1,43 while this process has not been shown to affect cytokine production.44 The renin-angiotensin system is upregulated during monocyte differentiation, and macrophages express relatively higher levels of AT1R and AT2 R compared with monocytes.11 The incubation of macrophages with Ang II via AT1R activation has been demonstrated to result in increased IL-6 production without affecting TNF-α.18,45 Further, an interaction between Ang II and enhanced TLR4 signaling has been reported.17,46, 47, 48 However, the interpretation of these findings has been complicated by the fact that the commonly used AT1R blockers, including losartan and candesartan, possess anti-inflammatory activities independent of the AT1R.18,44
Conversely, the anti-inflammatory role of the AT2R, which is generally considered to act as a functional antagonist of the AT1R, has been demonstrated in a number of in vitro and in vivo models.19, 20, 21, 22,49 Here, we report that the AT2R agonist C21 significantly lowered both TNF-α and IL-6 levels in association with increased production of the anti-inflammatory cytokine IL-10. Some degree of variation was observed in the absolute values of cytokines elicited by LPS in our experiments, which may be attributed to batch-to-batch variations in LPS levels. Nevertheless, in all cases, C21 treatment resulted in an approximate 50% decrease in pro-inflammatory cytokine levels. Because this altered cytokine profile could be abrogated by the AT2R antagonist PD123319, we conclude that these anti-inflammatory effects were associated with a specific AT2R-mediated response.
Our preliminary experiments (data not shown) suggested that Ang II did not stimulate the production of cytokines, which is in agreement with the findings by An et al.,18 who have reported that Ang II does not alter cytokine levels in the presence or absence of LPS in THP-1 macrophages. Larrayoz et al.44 have previously demonstrated that candesartan inhibits LPS-induced pro-inflammatory cytokine production by human monocytes, while in our study, it did not alter the cytokine levels. This might be explained by differences in the cell types and LPS doses used. In the present study, we used a dose of LPS that was 20 times higher than that used by Larrayoz et al.,44 and it is possible that candesartan may not be effective under conditions of excessive immune activation. Another critical difference between the two studies is the time of sample collection. We collected samples for cytokine estimation at 24 h post LPS administration as opposed to 2 h. Our data simply suggest that candesartan may not possess anti-inflammatory activities in THP-1 macrophages. It is very likely that in vivo, the blockade of AT1R results in anti-inflammatory effects due to its collective influences on other cell types, as previously demonstrated.
We found that pre-treatment with C21 in the presence of LPS also attenuated AT1R expression. The downregulation of AT1R in response to AT2R stimulation under pathophysiological conditions has been reported in a number of experimental models.29, 30, 31 In the present study, however, this observation may be unrelated to the anti-inflammatory response to the AT2R agonist because the increase in pro-inflammatory cytokine levels did not appear to be mediated by AT1R activation.
We have previously shown that AT2R stimulation results in enhanced IL-10 secretion by proximal tubule epithelial cells.22 A similar observation was reported in a specific subset of splenic CD8+AT2R+ T cells, which produced uncharacteristically high levels of IL-10 and AT2R following stimulation by Ang II as well as by C21, which further augmented IL-10 production.50 Here, we report that C21 alone increased IL-10 gene expression levels; however, this did not translate to increased IL-10 protein secretion, except in the presence of TLR4 activation by LPS. This could be a result of post-transcriptional modifications to IL-10 mRNA that have been shown to occur in immune cells as a means of regulating IL-10 production in the absence of inflammatory stimuli.51
Although there is considerable evidence demonstrating the anti-inflammatory effects of AT2R stimulation, the signaling pathways involved in mediating this response remain unclear and are still a subject of debate. Moreover, the cell types and experimental conditions used greatly influence the downstream signaling cascades activated by the AT2R. Typically, AT2R stimulation results in the activation of phosphatases, including MAP kinase phosphatase-152, 53, 54 and SH-2 domain-containing phosphatase-1,55, 56, 57 which ultimately leads to AT2R-mediated apoptosis. However, AT2R stimulation has also been shown to promote cellular differentiation via a sustained increase in ERK1/2 phosphorylation,58, 59, 60, 61 which is independent of cAMP-mediated signaling.62 In the present study, AT2R agonist pre-treatment resulted in a delayed increase in ERK1/2 phosphorylation, which was sustained for up to 24 h post LPS activation; however, treatment with the AT2R agonist alone did not promote ERK1/2 phosphorylation at any of the time points studied, nor was IL-10 detectable in the medium. Thus, it appears that LPS-mediated signaling pathways are required for the augmented IL-10 production by the AT2R agonist. On the basis of the protein expressions of the macrophage markers iNOS and MMR, C21 pre-treatment may prime macrophages, so that in the presence of an activating signal, such as LPS, their polarization to the alternatively activated, anti-inflammatory M2 phenotype is favored over the pro-inflammatory, classically activated M1 phenotype. In the present study, we used naïve PMA-differentiated macrophages, which were then stimulated by LPS. However, in the setting of chronic inflammation in vivo, a percentage of the macrophages are likely to be polarized to the M1 state. The effects of AT2R activation in these differentiated macrophages warrant further investigation.
In macrophages, multiple pathways exist that can regulate the production of IL-10, depending upon the activating stimulus.28,63, 64, 65, 66 Of these, activation of the p38 and ERK1/2 MAPKs has been shown to be critical for the induction of IL-10 synthesis.23, 24, 25, 26, 27, 28 We report that the inhibition of p38 activation partially abrogated the AT2R-mediated increase in IL-10, while the inhibition of ERK1/2 activation resulted in a complete lack of IL-10 production in response to AT2R stimulation, suggesting that p38 MAPK may contribute to, but is not essential for, AT2R-mediated IL-10 expression. This observation could also be linked to the altered kinetics of p38 MAPK phosphorylation in response to LPS in the presence or absence of AT2R agonist pre-treatment. However, the precise mechanisms that orchestrate these changes in MAPK phosphorylation over time require further investigation. Overall, our results regarding MAPK activation are in agreement with the in vivo study by Kaschina et al.,67 who have reported that treatment with C21 promotes p38 and ERK1/2 phosphorylation in a model of myocardial infarction.
Over the past decade, AT2R stimulation has emerged as a potential therapeutic target for the treatment of hypertension and end-organ damage,21,22,29,68,69 particularly in the presence of a concomitant AT1R blockade.70,71 Further, AT2R activation at the level of the kidney has been shown to promote vasodilation and natriuresis, thus conferring renoprotection in the setting of hypertension.29,72,73 Although the administration of C21 has been shown to have modest, if any, effects on lowering blood pressure,21,69,74, 75, 76 its protective effects on inflammation, oxidative stress, fibrosis and vascular remodeling underscore the potential benefit of the addition of an AT2R agonist to the currently used classical anti-hypertensive drugs to delay the progression of hypertension and end-organ damage. Here, we identify macrophages, which have a central role in the initiation and progression of hypertension-associated target organ damage, as an additional target of AT2R stimulation.
In conclusion, the present study demonstrated a novel anti-inflammatory role of AT2R stimulation in macrophages involving the attenuation of TLR4-mediated pro-inflammatory cytokine production. We further demonstrated that the ERK1/2-dependent increase in IL-10 production was a key event involved in mediating this anti-inflammatory response. Thus, stimulation of the AT2R may be beneficial in the treatment of hypertension due to its protective effects, not only on hemodynamic factors, such as vasodilation and Na+ excretion, but also as a consequence of the attenuation of inflammation and associated end-organ injury.
References
Bautista LE . Inflammation, endothelial dysfunction, and the risk of high blood pressure: Epidemiologic and biological evidence. J Hum Hypertens 2003; 17: 223–230.
Chrysohoou C, Pitsavos C, Panagiotakos DB, Skoumas J, Stefanadis C . Association between prehypertension status and inflammatory markers related to atherosclerotic disease: The ATTICA Study. Am J Hypertens 2004; 17: 568–573.
Heijnen BFJ, Essen H, Schalkwijk CG, Janssen BJA, Struijker-Boudie HAJ . Renal inflammatory markers during the onset of hypertension in spontaneously hypertensive rats. Hypertens Res 2014; 37: 100–109.
Stumpf C, John S, Jukic J, Yilmaz A, Raaz D, Schmieder RE, Daniel WG, Garlichs CD . Enhanced levels of platelet P-selectin and circulating cytokines in young patients with mild arterial hypertension. J Hypertens 2005; 23: 995–1000.
Clozel M, Kuhn H, Hefti F, Baumgartner HR . Endothelial dysfunction and subendothelial monocyte macrophages in hypertension. Effect of angiotensin converting enzyme inhibition. Hypertension 1991; 18: 132–141.
Haller H, Behrend M, Park JK, Schaberg T, Luft FC, Distler A . Monocyte infiltration and c-fms expression in hearts of spontaneously hypertensive rats. Hypertension 1995; 25: 132–138.
Johnson RJ, Alpers CE, Yoshimura A, Lombardi D, Pritzl P, Floege J, Schwartz SM . Renal injury from angiotensin II-mediated hypertension. Hypertension 1992; 19: 464–474.
Chen NG, Abbasi F, Lamendola C, McLaughlin T, Cooke JP, Tsao PS, Reaven GM . Mononuclear cell adherence to cultured endothelium is enhanced by hypertension and insulin resistance in healthy nondiabetic volunteers. Circulation 1999; 100: 940–943.
Machnik A, Neuhofer W, Jantsch J, Dahlmann A, Tammela T, Machura K, Park JK, Beck FX, Müller DN, Derer W, Goss J, Ziomber A, Dietsch P, Wagner H, van Rooijen N, Kurtz A, Hilgers KF, Alitalo K, Eckardt KU, Luft FC, Kerjaschki D, Titze J . Macrophages regulate salt-dependent volume and blood pressure by a vascular endothelial growth factor-C-dependent buffering mechanism. Nat Med 2009; 15: 545–552.
Kriska T, Cepura C, Gauthier KM, Campbell WB . Role of macrophage PPARγ in experimental hypertension. Am J Physiol 2014; 306: H26–H32.
Okamura A, Rakugi H, Ohishi M, Yanagitani Y, Takiuchi S, Moriguchi K, Fennessy PA, Higaki J, Ogihara T . Upregulation of renin-angiotensin system during differentiation of monocytes to macrophages. J Hypertens 1999; 17: 537–545.
Ma LJ, Corsa BA, Zhou J, Yang H, Li H, Tang YW, Babaev VR, Major AS, Linton MF, Fazio S, Hunley TE, Kon V, Fogo AB . Angiotensin type 1 receptor modulates macrophage polarization and renal injury in obesity. Am J Physiol Renal Physiol 2011; 300: F1203–F1213.
Rafatian N, Milne RW, Leenen FH, Whitman SC . Role of renin-angiotensin system in activation of macrophages by modified lipoproteins. Am J Physiol Heart Circ Physiol 2013; 305: H1309–H1320.
Yamamoto S, Yancey PG, Zuo Y, Ma LJ, Kaseda R, Fogo AB, Ichikawa I, Linton MF, Fazio S, Kon V . Macrophage polarization by angiotensin II-type 1 receptor aggravates renal injury-acceleration of atherosclerosis. Arterioscler Thromb Vasc Biol 2011; 31: 2856–2864.
Bomfim GF, Dos Santos RA, Oliveira MA, Giachini FR, Akamine EH, Tostes RC, Fortes ZB, Webb RC, Carvalho MHC . Toll-like receptor 4 contributes to blood pressure regulation and vascular contraction in spontaneously hypertensive rats. Clin Sci 2012; 122: 535–543.
Marketou ME, Kontaraki JE, Zacharis EA, Kochiadakis GE, Giaouzaki A, Chlouverakis G, Vardas PE . TLR2 and TLR4 gene expression in peripheral monocytes in nondiabetic hypertensive patients: the effect of intensive blood pressure-lowering. J Clin Hypertens (Greenwich) 2012; 14: 330–335.
Wolf G, Bohlender J, Bondeva T, Roger T, Thaiss F, Wenzel UO . Angiotensin II upregulates toll-like receptor 4 on mesangial cells. J Am Soc Nephrol 2006; 17: 1585–1593.
An J, Nakajima T, Kuba K, Kimura A . Losartan inhibits LPS-induced inflammatory signaling through a PPARgamma-dependent mechanism in human THP-1 macrophages. Hypertens Res 2010; 33: 831–835.
Rompe F, Artuc M, Hallberg A, Alterman M, Stroder K, Thone-Reineke C, Reichenback A, Schacherl J, Dahlof B, Bader M, Alenina N, Schwaninger M, Zuberbier T, Funke-Kaiser H, Schmidt C, Schunck W, Unger T, Steckelings UM . Direct angiotensin II type 2 receptor stimulation acts as anti-inflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor κB. Hypertension 2010; 55: 924–931.
Abadir PM, Walton JD, Carey RM, Siragy HM . Angiotensin II type 2 receptors modulate inflammation through signal transducer and activator transcription proteins 3 phosphorylation and TNF-α production. J Interferon Cytokine Res 2011; 31: 471–474.
Matavelli LC, Jiang H, Siragy HM . Angiotensin AT2 receptor stimulation inhibits early renal inflammation in renovascular hypertension. Hypertension 2011; 57: 308–313.
Dhande IS, Ali Q, Hussain T . Proximal tubule Angiotensin AT2 receptors mediate an anti-inflammatory response via interleukin-10: role in renoprotection in obese rats. Hypertension 2013; 61: 1218–1226.
Saraiva M, O’Garra A . The regulation of Interleukin-10 production by immune cells. Nat Rev Immunol 2010; 10: 170–181.
Zhang P, Martin M, Michalek SM, Katz J . Role of mitogen-activated protein kinases and NF-κB in the regulation of proinflammatory and anti-inflammatory cytokines by Porphyromonas gingivalis hemagglutinin B. Infect Immun 2005; 73: 3990–3998.
Ma W, Lim W, Gee K, Aucoin S, Nandan D, Kozlowski M, Diaz-Mitoma F, Kumar A . The p38 mitogen-activated kinase pathway regulates the human interleukin-10 promoter via the activation of Sp1 transcription factor in lipopolysaccharide-stimulated human macrophages. J Biol Chem 2001; 276: 13664–13674.
Yi AK, Yoon JG, Yeo SJ, Hong SC, English BK, Krieg AM . Role of mitogen-activated protein kinases in CpG DNA-mediated IL-10 and IL-12 production: central role of extracellular signal-regulated kinase in the negative feedback loop of the CpG DNA-mediated Th1 response. J Immunol 2002; 168: 4711–4720.
Koscsó B, Csóka B, Selmeczy Z, Himer L, Pacher P, Virág L, Haskó G . Adenosine augments IL-10 production by microglial cells through an A2B adenosine receptor-mediated process. J Immunol 2012; 188: 445–453.
Chanteux H, Guisset AC, Pilette C, Sibille Y . LPS induces IL-10 production by human alveolar macrophages via MAPKinases- and Sp1-dependent mechanisms. Respir Res 2007; 8: 71.
Ali Q, Wu Y, Hussain T . Chronic AT2 receptor activation increases renal ACE2 activity, attenuates AT1 receptor function and blood pressure in obese Zucker rats. Kidney Int 2013; 84: 931–939.
Shum M, Pinard S, Guimond MO, Labbé SM, Roberge C, Baillargeon JP, Langlois MF, Alterman M, Wallinder C, Hallberg A, Carpentier AC, Gallo-Payet N . Angiotensin II type 2 receptor promotes adipocyte differentiation and restores adipocyte size in high-fat/high-fructose diet-induced insulin resistance in rats. Am J Physiol Endocrinol Metab 2013; 304: E197–E210.
Yang J, Chen C, Ren H, Han Y, He D, Zhou L, Hopfer U, Jose PA, Zeng C . Angiotensin II AT(2) receptor decreases AT(1) receptor expression and function via nitric oxide/cGMP/Sp1 in renal proximal tubule cells from Wistar-Kyoto rats. J Hypertens 2012; 30: 1176–1184.
Lucas M, Zhang X, Prasanna V, Mosser DM . ERK activation following macrophage FcgammaR ligation leads to chromatin modifications at the IL-10 locus. J Immunol 2005; 175: 469–477.
Kaiser F, Cook D, Papoutsopoulou S, Rajsbaum R, Wu X, Yang HT, Grant S, Ricciardi-Castagnoli P, Tsichlis PN, Ley SC, O'Garra A . TPL-2 negatively regulates interferon-beta production in macrophages and myeloid dendritic cells. J Exp Med 2009; 206: 1863–1871.
Pastore L, Tessitore A, Martinotti S, Toniato E, Alesse E, Bravi MC, Ferri C, Desideri G, Gulino A, Santucci A . Angiotensin II stimulates intercellular adhesion molecule-1 (ICAM-1) expression by human vascular endothelial cells and increases soluble ICAM-1 release in vivo. Circulation 1999; 100: 1646–1652.
Pueyo ME, Gonzalez W, Nicoletti A, Savoie F, Arnal JF, Michel JB . Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress. Arterioscler Thromb Vasc Biol 2000; 20: 645–651.
Rice EK, Tesch GH, Cao Z, Cooper ME, Metz Christine N, Bucala R, Atkins RC, Nikolic-Paterson DJ . Induction of MIF synthesis and secretion by tubular epithelial cells: a novel action of angiotensin II. Kidney Int 2003; 63: 1265–1275.
Lapteva N, Ide K, Nieda M, Ando Y, Hatta-Ohashi Y, Minami M, Dymshits G, Egawa K, Juji T, Tokunaga K . Activation and suppression of renin-angiotensin system in human dendritic cells. Biochem Biophys Res Commun 2002; 296: 194–200.
Muller DN, Shagdarsuren E, Park JK, Dechend R, Mervaala E, Hampich F, Fiebeler A, Ju X, Finckenberg P, Theuer J, Viedt C, Kreuzer J, Heidecke H, Haller H, Zenke M, Luft FC . Immunosuppressive treatment protects against angiotensin II-induced renal damage. Am J Pathol 2002; 161: 1679–1693.
Nahmod KA, Vermeulen ME, Raiden S, Salamone G, Gamberale R, Fernandez-Calotti P, Alvarez A, Nahmod V, Giordano M, Geffner JR . Control of dendritic cell differentiation by angiotensin II. FASEB J 2003; 17: 491–493.
Crowley SD, Frey CW, Gould SK, Griffiths R, Ruiz P, Burchette JL, Howell DN, Makhanova N, Yan M, Kim HS, Tharaux PL, Coffman TM . Stimulation of lymphocyte responses by angiotensin II promotes kidney injury in hypertension. Am J Physiol Renal Physiol 2008; 295: F515–F524.
Jurewicz M, McDermott DH, Sechler JM, Tinckam K, Takakura A, Carpenter CB, Milford E, Abdi R . Human T and natural killer cells possess a functional renin-angiotensin system: further mechanisms of angiotensin II-induced inflammation. J Am Soc Nephrol 2007; 18: 1093–1102.
Kvakan H, Kleinewietfeld M, Qadri F, Park JK, Fischer R, Schwarz I, Rahn HP, Plehm R, Wellner M, Elitok S, Gratze P, Dechend R, Luft FC, Muller DN . Regulatory T cells ameliorate angiotensin II-induced cardiac damage. Circulation 2009; 119: 2904–2912.
Dai Q, Xu M, Yao M, Sun B . Angiotensin AT1 receptor antagonists exert anti-inflammatory effects in spontaneously hypertensive rats. Br J Pharmacol 2007; 152: 1042–1048.
Larrayoz IM, Pang T, Benicky J, Pavel J, Sánchez-Lemus E, Saavedra JM . Candesartan reduces the innate immune response to lipopolysaccharide in human monocytes. J Hypertens 2009; 27: 2365–2376.
Nakamura A, Johns EJ, Imaizumi A, Yanagawa Y, Kohsaka T . Effect of beta(2)-adrenoceptor activation and angiotensin II on tumour necrosis factor and interleukin 6 gene transcription in the rat renal resident macrophage cells. Cytokine 1999; 11: 759–765.
Ji Y, Liu J, Wang Z, Liu N . Angiotensin II induces inflammatory response partly via toll-like receptor 4-dependent signaling pathway in vascular smooth muscle cells. Cell Physiol Biochem 2009; 23: 265–276.
Bondeva T, Roger T, Wolf G . Differential regulation of Toll-Like Receptor 4 gene expression in renal cells by angiotensin ii: dependency on AP1 and PU.1 transcriptional sites. Am J Nephrol 2007; 27: 308–314.
Wu J, Yang X, Zhang YF, Zhou SF, Zhang R, Dong XQ, Fan JJ, Liu M, Yu XQ . Angiotensin II up-regulated Toll-like receptor 4 and enhances lipopolysaccharide-induced CD40 expression in rat peritoneal mesothelial cells. Inflamm Res 2009; 58: 473–482.
Sabuhi R, Ali Q, Asghar M, Al-Zamily NRH, Hussain T . Role of angiotensin II AT2 receptor in inflammation and oxidative stress: Opposing effects in lean and obese rats. Am J Renal Physiol 2011; 300: F700–F706.
Curato C, Slavic S, Dong J, Skorska A, Altarche-Xifro W, Miteva K, Kaschina E, Thiel A, Imboden H, Wang I, Steckelings U, Steinhoff G, Unger T, Li J . Identification of non-cytotoxic and IL-10 producing CD8+AT2R+ T-cell population in response to ischemic heart injury. J Immunol 2010; 185: 6286–6293.
Powell MJ, Thompson SA, Tone Y, Waldmann H, Tone M . Posttranscriptional regulation of IL-10 gene expression through sequences in the 3'-untranslated region. J Immunol 2000; 165: 292–296.
Hayashida W, Horiuchi M, Dzau VJ . Intracellular third loop domain of angiotensin II type-2 receptor. Role in mediating signal transduction and cellular function. J Biol Chem 1996; 271: 21985–21992.
Yamada T, Horiuchi M, Dzau VJ . Angiotensin II type 2 receptor mediates programmed cell death. Proc Natl Acad Sci 1996; 93: 156–160.
Horiuchi M, Hayashida W, Kambe T, Yamada T, Dzau VJ . Angiotensin type 2 receptor dephosphorylates Bcl-2 by activating mitogen-activated protein kinase phosphatase-1 and induces apoptosis. J Biol Chem 1997; 272: 19022–19026.
Bedecs K, Elbaz N, Sutren M, Masson M, Susini C, Strosberg AD, Nahmias C . Angiotensin II type 2 receptors mediate inhibition of mitogen-activated protein kinase cascade and functional activation of SHP-1 tyrosine phosphatase. Biochem J 1997; 325: 449–454.
Elbaz N, Bedecs K, Masson M, Sutren M, Strosberg AD, Nahmias C . Functional trans-inactivation of insulin receptor kinase by growth-inhibitory angiotensin II AT2 receptor. Mol Endocrinol 2000; 14: 795–804.
Shibasaki Y, Matsubara H, Nozawa Y, Mori Y, Masaki H, Kosaki A, Tsutsumi Y, Uchiyama Y, Fujiyama S, Nose A, Iba O, Tateishi E, Hasegawa T, Horiuchi M, Nahmias C, Iwasaka T . Angiotensin II type 2 receptor inhibits epidermal growth factor receptor transactivation by increasing association of SHP-1 tyrosine phosphatase. Hypertension 2001; 38: 367–372.
Gendron L, Laflamme L, Rivard N, Asselin C, Payet MD, Gallo-Payet N . Signals from the AT2 (angiotensin type 2) receptor of angiotensin II inhibit p21ras and activate MAPK (mitogen-activated protein kinase) to induce morphological neuronal differentiation in NG108-15 cells. Mol Endocrinol 1999; 13: 1615–1626.
Stroth U, Blume A, Mielke K, Unger T . Angiotensin AT(2) receptor stimulates ERK1 and ERK2 in quiescent but inhibits ERK in NGF-stimulated PC12W cells. Brain Res Mol Brain Res 2000; 78: 175–180.
Hansen JL, Servant G, Baranski TJ, Fujita T, Iiri T, Sheikh SP . Functional reconstitution of the angiotensin II type 2 receptor and G(i) activation. Circ Res 2000; 87: 753–759.
De Paolis P, Porcellini A, Savoia C, Lombardi A, Gigante B, Frati G, Rubattu S, Musumeci B, Volpe M . Functional cross-talk between angiotensin II and epidermal growth factor receptors in NIH3T3 fibroblasts. J Hypertens 2002; 20: 693–699.
Gendron L, Oligny JF, Payet MD, Gallo-Payet N . Cyclic AMP-independent involvement of Rap1/B-Raf in the angiotensin II AT2 receptor signaling pathway in NG108-15 cells. J Biol Chem 2003; 278: 3606–3614.
MacKenzie KF, Clark K, Naqvi S, McGuire VA, Nöehren G, Kristariyanto Y, van den Bosch M, Mudaliar M, McCarthy PC, Pattison MJ, Pedrioli PG, Barton GJ, Toth R, Prescott A, Arthur JS . PGE(2) induces macrophage IL-10 production and a regulatory-like phenotype via a protein kinase A-SIK-CRTC3 pathway. J Immunol 2013; 190: 565–577.
Okenwa C, Kumar A, Rego D, Konarski Y, Nilchi L, Wright K, Kozlowski M . SHP-1-Pyk2-Src protein complex and p38 MAPK pathways independently regulate IL-10 production in lipopolysaccharide-stimulated macrophages. J Immunol 2013; 191: 2589–2603.
Elcombe SE, Naqvi S, Van Den Bosch MW, MacKenzie KF, Cianfanelli F, Brown GD, Arthur JS . Dectin-1 regulates IL-10 production via a MSK1/2 and CREB dependent pathway and promotes the induction of regulatory macrophage markers. PLoS ONE 2013; 8: e60086.
Iyer SS, Ghaffari AA, Cheng G . Lipopolysaccharide-mediated IL-10 transcriptional regulation requires sequential induction of type I IFNs and IL-27 in macrophages. J Immunol 2010; 185: 6599–6607.
Kaschina E, Grzesiak A, Li J, Foryst-Ludwig A, Timm M, Rompe F, Sommerfeld M, Kemnitz UR, Curato C, Namsolleck P, Tschöpe C, Hallberg A, Alterman M, Hucko T, Paetsch I, Dietrich T, Schnackenburg B, Graf K, Dahlöf B, Kintscher U, Unger T, Steckelings UM . Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction? Circulation 2008; 118: 2523–2532.
Carey RM, Padia SH . Role of angiotensin AT(2) receptors in natriuresis: intrarenal mechanisms and therapeutic potential. Clin Exp Pharmacol Physiol 2013; 40: 527–534.
Rehman A, Leibowitz A, Yamamoto N, Rautureau Y, Paradis P, Schiffrin EL . Angiotensin type 2 receptor agonist compound 21 reduces vascular injury and myocardial fibrosis in stroke-prone spontaneously hypertensive rats. Hypertension 2012; 59: 291–299.
Carey RM, Howell NL, Jin XH, Siragy HM . Angiotensin type 2 receptor-mediated hypotension in angiotensin type-1 receptor-blocked rats. Hypertension 2001; 38: 1272–1277.
Barber MN, Sampey DB, Widdop RE . AT(2) receptor stimulation enhances antihypertensive effect of AT(1) receptor antagonist in hypertensive rats. Hypertension 1999; 34: 1112–1116.
Ali Q, Hussain T . AT2 receptor non-peptide agonist C21 promotes natriuresis in obese Zucker rats. Hypertens Res 2012; 35: 654–660.
Hilliard LM, Jones ES, Steckelings UM, Unger T, Widdop RE, Denton KM . Sex-specific influence of angiotensin type 2 receptor stimulation on renal function: a novel therapeutic target for hypertension. Hypertension 2012; 59: 409–414.
Bosnyak S, Welungoda IK, Hallberg A, Alterman M, Widdop RE, Jones ES . Stimulation of angiotensin AT2 receptors by the non-peptide agonist, Compound 21, evokes vasodepressor effects in conscious spontaneously hypertensive rats. Br J Pharmacol 2010; 159: 709–716.
Paulis L, Becker ST, Lucht K, Schwengel K, Slavic S, Kaschina E, Thöne-Reineke C, Dahlöf B, Baulmann J, Unger T, Steckelings UM . Direct angiotensin II type 2 receptor stimulation in Nω-nitro-L-arginine-methyl ester-induced hypertension: the effect on pulse wave velocity and aortic remodeling. Hypertension 2012; 59: 485–492.
Gelosa P, Pignieri A, Fändriks L, de Gasparo M, Hallberg A, Banfi C, Castiglioni L, Turolo L, Guerrini U, Tremoli E, Sironi L . Stimulation of AT2 receptor exerts beneficial effects in stroke-prone rats: focus on renal damage. J Hypertens 2009; 27: 2444–2451.
Acknowledgements
This study was supported by grant R01 DK-61578 from the National Institutes of Health, which was awarded to TH. The authors also wish to thank Dr Jianzhong Shen (Auburn University) for providing the THP-1 cells. PD123319 was a generous gift from Pfizer. Candesartan was a generous gift from AstraZeneca.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on Hypertension Research website
Supplementary information
Rights and permissions
About this article
Cite this article
Dhande, I., Ma, W. & Hussain, T. Angiotensin AT2 receptor stimulation is anti-inflammatory in lipopolysaccharide-activated THP-1 macrophages via increased interleukin-10 production. Hypertens Res 38, 21–29 (2015). https://doi.org/10.1038/hr.2014.132
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/hr.2014.132
Keywords
This article is cited by
-
Angiotensin II type 2 receptor activation preserves megalin in the kidney and prevents proteinuria in high salt diet fed rats
Scientific Reports (2023)
-
Angiotensin II type 2 receptor agonist attenuates LPS-induced acute lung injury through modulating THP-1-derived macrophage reprogramming
Naunyn-Schmiedeberg's Archives of Pharmacology (2023)
-
Supervillin Contributes to LPS-induced Inflammatory Response in THP-1 Cell-derived Macrophages
Inflammation (2022)
-
Association study indicates combined effect of interleukin-10 and angiotensin-converting enzyme in basal cell carcinoma development
Archives of Dermatological Research (2021)
-
Counter-regulatory renin–angiotensin system in cardiovascular disease
Nature Reviews Cardiology (2020)